TrialGynecologic oncology2015

Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.

Carol Aghajanian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.